Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease… Read more
Unicycive Therapeutics Inc (UNCY) - Total Liabilities
Latest total liabilities as of September 2025: $13.13 Million USD
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has total liabilities worth $13.13 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Unicycive Therapeutics Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Unicycive Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Unicycive Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Unicycive Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Evergrande Group
F:EV1
|
Germany | €2.39 Trillion |
|
Kuo Yang Construction Co Ltd
TW:2505
|
Taiwan | NT$11.93 Billion |
|
CTT Systems AB
ST:CTT
|
Sweden | Skr93.80 Million |
|
GZ4
F:GZ4
|
Germany | €5.37 Billion |
|
Qinghai Spring Medicinal Resources Technology Co Ltd
SHG:600381
|
China | CN¥45.34 Million |
|
Forest Packaging Group Co Ltd
SHG:605500
|
China | CN¥1.62 Billion |
|
MK Electron Co. Ltd
KQ:033160
|
Korea | ₩1.48 Trillion |
Liability Composition Analysis (2018–2024)
This chart breaks down Unicycive Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Unicycive Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Unicycive Therapeutics Inc (2018–2024)
The table below shows the annual total liabilities of Unicycive Therapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $24.24 Million | +34.65% |
| 2023-12-31 | $18.00 Million | +448.11% |
| 2022-12-31 | $3.28 Million | +45.31% |
| 2021-12-31 | $2.26 Million | -21.39% |
| 2020-12-31 | $2.88 Million | +218.38% |
| 2019-12-31 | $903.00K | -26.88% |
| 2018-12-31 | $1.24 Million | -- |